Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic

Émilien Schultz 1, 2 Léo Mignot Jeremy K Ward Daniela Boaventura Silva Bomfim Christian Chabannon Julien Mancini
2 SESSTIM - U1252 INSERM - AMU - UMR 259 IRD - “Cancer, Biomedicine & Society” group
SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
Abstract : During the COVID-19 pandemic, public debates overtly addressed the promises of new innovative treatments. Many of these debates pitted those who advocated for the development of new treatments by pharmaceutical companies against those who favored the repositioning of existing drugs. Our study explored perceptions of the association between drug novelty and effectiveness as well as perceptions of the role of the pharmaceutical industry in drug development. Data were collected in January 2021 from a quota sample of the French population aged 18–75 years (N = 1,000) during the second round of the “Health Literacy Survey 2019” (HLS19). We tested the hypothesis that individuals with a high level of familiarity with the health care system and those with a high level of trust in institutions are more likely to agree that new drugs are more effective than old ones and that drug development should be driven by the pharmaceutical industry. A quarter (25%) of respondents agreed that new drugs are always more effective than old ones. Agreement with this statement was stronger among respondents with a high level of familiarity with the health care system (as measured by the Navigational Health Literacy score, OR 3.34 [2.13-5.24]) and among those with a high level of trust in pharmaceutical companies or politicians. A high level of trust in pharmaceutical companies was reported by 42% of respondents, and 43% agreed that drug development should be driven by the pharmaceutical industry. Respondents who agreed that new drugs are always more effective than old ones were almost four times more likely to agree that drug development should be driven by the pharmaceutical industry (OR 3.85 [2.76-5.39]). A better understanding of public attitudes towards new treatments is needed to elucidate individual preferences in health care and their consequences on health behavior.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

https://halshs.archives-ouvertes.fr/halshs-03448961
Contributor : Emilien Schultz Connect in order to contact the contributor
Submitted on : Thursday, November 25, 2021 - 2:31:50 PM
Last modification on : Thursday, January 20, 2022 - 9:42:02 AM

File

Schultz et al - preprint 24112...
Files produced by the author(s)

Identifiers

  • HAL Id : halshs-03448961, version 1

Citation

Émilien Schultz, Léo Mignot, Jeremy K Ward, Daniela Boaventura Silva Bomfim, Christian Chabannon, et al.. Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic. 2021. ⟨halshs-03448961⟩

Share

Metrics

Les métriques sont temporairement indisponibles